Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
Results for “Novartis”
Sponsor: Novartis Pharmaceuticals
Asthma
Bulgaria, Colombia, Guatemala, Hungary, Poland +3 more
- A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.Recruiting
Sponsor: Novartis Pharmaceuticals
Chagas Disease
United States, Argentina, Brazil, Colombia
- A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic AnemiaActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Warm Autoimmune Hemolytic Anemia (wAIHA)
United States, Argentina, Australia, China, France +11 more
- Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCRecruiting
Sponsor: Novartis Pharmaceuticals
Prostate Cancer
United States, Australia, Brazil, China, Hong Kong +6 more
- A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue FeverRecruiting
Sponsor: Novartis Pharmaceuticals
Dengue
Brazil, Colombia, India, Malaysia, Mexico +2 more
- Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLTActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Prostate Cancer
United States, Australia, Canada, France
Sponsor: Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
Argentina, Brazil, Bulgaria, Canada, Czechia +18 more
- A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.Active Not Recruiting
Sponsor: Novartis Pharmaceuticals
Sjogrens Syndrome
United States, Argentina, Australia, Austria, Belgium +30 more
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruiting
Sponsor: Novartis Pharmaceuticals
Advanced Solid Tumor · Diffuse Large B Cell Lymphoma · Lymphoma, T-Cell · Mesothelioma, Malignant
United States, France, Italy, Poland, South Korea +2 more
Sponsor: Novartis Pharmaceuticals
Chronic Spontaneous Urticaria (CSU)
United States
Sponsor: Novartis Pharmaceuticals
Chronic Kidney Disease
United States, Germany
Sponsor: Novartis Pharmaceuticals
Atopic Dermatitis
United States, Argentina, Canada, China, Czechia +12 more
Sponsor: St Vincent's Hospital, Sydney
Breast Cancer
Australia
- Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth SpectrumActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
United States, Canada, China, France, Germany +7 more
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)Active Not Recruiting
Sponsor: Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
United States, Argentina, Austria, Belgium, Brazil +29 more
Sponsor: Novartis Pharmaceuticals
Sjögren´s Disease
United States, Australia, Canada
Sponsor: Novartis Pharmaceuticals
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer · Advanced Solid Tumors Harboring the KRAS G12C Mutation
Belgium, Canada, China, Denmark, France +4 more
Sponsor: Novartis Pharmaceuticals
Melanoma · Non Small Cell Lung Cancer · Solid Tumor · Rare Cancers
United States, Argentina, Austria, China, Denmark +7 more
- Frontline Asciminib Combination in Chronic Phase CMLActive Not Recruiting
Sponsor: University of Jena
Chronic Myeloid Leukemia
Germany
- A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)Active Not Recruiting
Sponsor: Novartis Pharmaceuticals
Prostatic Cancer, Castration-Resistant
United States, Australia, Austria, Canada, China +10 more
Sponsor: Novartis Pharmaceuticals
Lymphatic Malformations
United States, Argentina, Australia, Belgium, Czechia +7 more
Sponsor: University of California, San Francisco
Recurrent World Health Organization (WHO) Grade II Glioma · Low-grade Glioma · High-Grade Glioma (HGG)
United States
- A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) PatientsNot Yet Recruiting
Sponsor: Novartis Pharmaceuticals
Radioiodine-refractory Differentiated Thyroid Cancer
Sponsor: Duke University
Percutaneous Coronary Intervention · Peripheral Endovascular Intervention
United States
- A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate CancerActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Prostate Cancer Metastatic
United States